Ketamine Hydrochloride Patent Expiration

Ketamine Hydrochloride was first introduced by Ph Health Ltd in its drug Ketalar on Approved Prior to Jan 1, 1982. 8 different companies have introduced drugs containing Ketamine Hydrochloride.


About Veterinary Ketamine Hydrochloride

Ketamine Hydrochloride is used in drugs marketed by 5 different companies: Cronus Pharma Specialities India Private Ltd, Elanco Us Inc, Dechra Veterinary Products Llc, Boehringer Lngelheim Animal Health Usa Inc, Zoetis Inc.

Other drugs containing Ketamine Hydrochloride are: Vetalar , Ketamine hydrochloride injection, usp , Ketamine hydrochloride injection , Ketaset .

Ketamine Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List



Clinical Trials

Recent Clinical Trials on Ketamine Hydrochloride:

Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Neurobiology of Suicide National Institute of Mental Health (NIMH) NA RECRUITING
(Sep 4, 2026)
PHASE2
The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy Madeline Fields NA COMPLETED
(Sep 1, 2026)
PHASE2
Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients Hospital Italiano de Buenos Aires NA RECRUITING
(Aug 1, 2026)
PHASE2
(2R,6R)-Hydroxynorketamine for the Treatment of Neuropathic Pain Rush University Medical Center NA RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2
Ketamine Assisted Psychotherapy for Treating Comorbid Chronic Pain and PTSD Dr. Yuliya Knyahnytska NA RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2
Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) Joshua Rosenblat NA RECRUITING
(Jul 1, 2026)
PHASE2
Predictors of Intravenous Ketamine Response in TRD Abraham Nunes NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3
Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus New York State Psychiatric Institute NA COMPLETED
(Mar 1, 2026)
PHASE2
Ketamine Treatment of Youth Suicide Attempters Tatiana Falcone, MD NA RECRUITING
(Mar 1, 2026)
PHASE3


Ketamine Hydrochloride Generic API Manufacturers

Several generic applications have been filed for Ketamine Hydrochloride. The first generic version for Ketamine Hydrochloride was by Hikma Pharmaceuticals Usa Inc and was approved on Mar 22, 1996. And the latest generic version is by Baxter Healthcare Corp and was approved on Aug 11, 2026.

Given below is the list of companies who have filed for Ketamine Hydrochloride generic, along with the locations of their manufacturing plants worldwide.